New York State Common Retirement Fund Has $5.96 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

New York State Common Retirement Fund increased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 2.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 161,457 shares of the biotechnology company’s stock after purchasing an additional 4,200 shares during the period. New York State Common Retirement Fund owned approximately 0.06% of Exelixis worth $5,961,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Exelixis by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company’s stock valued at $979,994,000 after purchasing an additional 121,750 shares during the period. LSV Asset Management boosted its position in Exelixis by 0.8% in the fourth quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company’s stock valued at $272,056,000 after buying an additional 67,470 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in Exelixis by 10.2% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company’s stock worth $254,110,000 after purchasing an additional 708,312 shares in the last quarter. Invesco Ltd. boosted its position in Exelixis by 308.1% during the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock worth $132,376,000 after buying an additional 3,001,204 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Exelixis by 25.7% in the fourth quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company’s stock valued at $132,101,000 after acquiring an additional 810,857 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In related news, EVP Patrick J. Haley sold 34,387 shares of the firm’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $44.06, for a total value of $1,515,091.22. Following the completion of the transaction, the executive vice president directly owned 412,072 shares of the company’s stock, valued at $18,155,892.32. This trade represents a 7.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sue Gail Eckhardt sold 18,838 shares of the firm’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $42.74, for a total transaction of $805,136.12. Following the transaction, the director owned 21,380 shares of the company’s stock, valued at approximately $913,781.20. This represents a 46.84% decrease in their position. The disclosure for this sale can be found here. Insiders sold 458,113 shares of company stock valued at $21,024,817 in the last quarter. Corporate insiders own 2.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EXEL. Bank of America raised their target price on Exelixis from $45.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 5th. Barclays lifted their price objective on shares of Exelixis from $29.00 to $40.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 10th. Stephens raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $29.00 to $60.00 in a report on Tuesday, June 24th. Benchmark restated a “neutral” rating on shares of Exelixis in a research report on Monday, June 23rd. Finally, Jefferies Financial Group set a $50.00 price objective on shares of Exelixis and gave the stock a “buy” rating in a research report on Tuesday, June 24th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.28.

Exelixis Trading Down 0.9%

Shares of EXEL stock opened at $44.47 on Monday. Exelixis, Inc. has a twelve month low of $22.20 and a twelve month high of $49.62. The firm has a fifty day simple moving average of $43.17 and a 200-day simple moving average of $38.47. The company has a market capitalization of $12.13 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 0.89 and a beta of 0.28.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.